百洋醫藥(301015.SZ)：擬收購百洋製藥、百洋投資、百洋伊仁及百洋康合股權
格隆匯5月20日丨百洋醫藥(301015.SZ)公佈，公司擬以現金收購上海百洋製藥股份有限公司(簡稱“百洋製藥”)60.199%股權，本次交易以資產評估機構出具的評估報吿為定價參考，具體安排如下：
(1)以49,418.51萬元收購百洋醫藥集團有限公司(以下簡稱“百洋集團”)持有青島百洋投資集團有限公司(以下簡稱“百洋投資”)100.000%的股權；
(2)以8,856.86萬元收購百洋集團持有青島百洋伊仁投資管理有限公司(以下簡稱“百洋伊仁”)100.000%的股權；
(3)以629.564萬元收購百洋集團持有北京百洋康合科技有限公司(以下簡稱“百洋康合”)40.000%的股權；
(4)以7,591.3814萬元收購百洋集團持有百洋製藥4.752%的股權；
(5)以19,039.1276萬元收購青島匯鑄百洋健康產業投資基金(有限合夥)(以下簡稱“匯鑄百洋”)持有百洋製藥11.918%的股權；
(6)以2,468.1644萬元收購青島菩提永和投資管理中心(有限合夥)(以下簡稱“菩提永和”)持有百洋製藥的1.545%股權。
本次交易完成後，百洋製藥、百洋投資、百洋伊仁及百洋康合(以下統稱為“標的公司”)將被納入公司合併報表範圍。
本次交易完成後，百洋醫藥控制百洋製藥61.794%股權，直接或間接方式持有百洋製藥共60.199%的股權，是百洋製藥的控股股東。
本次交易完成後，由百洋製藥控股的青島百洋製藥有限公司(以下簡稱“青島百洋”)同時納入公司合併報表範圍，其中，持有青島百洋6.667%股權的少數股東青島百洋醫藥大健康投資管理中心(有限合夥)的執行事務合夥人是公司控股股東百洋集團間接控制的企業；公司收購百洋投資之後，由百洋投資控股的百洋濟雅同時納入公司合併報表範圍，其中，持有百洋濟雅16.800%股權的少數股東王必全為公司副總經理，是公司的關聯自然人。本次交易構成公司與關聯方的共同投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
